How much did Novacyt achieve in EBIT for the current year?
In the current year, Novacyt has achieved an EBIT of 19.81 M GBP.
Novacyt EBIT 2024
Novacyt EBIT
19.81 M GBP
Ticker
ALNOV.PA
ISIN
FR0010397232
WKN
A12CFH
In 2024, Novacyt's EBIT was 19.81 M GBP, a -220.69% increase from the -16.41 M GBP EBIT recorded in the previous year.
The Novacyt EBIT history
| YEAR | EBIT (undefined GBP) |
|---|---|
| 2025e | 2.19 |
| 2024e | 19.81 |
| 2023 | -16.41 |
| 2022 | -15.73 |
| 2021 | 1.26 |
| 2020 | 174.69 |
| 2019 | -1.18 |
| 2018 | -0.85 |
| 2017 | -1.66 |
| 2016 | -3.4 |
| 2015 | -3.31 |
| 2014 | -3.62 |
| 2013 | -1.06 |
| 2012 | -0.57 |
| 2011 | -0.69 |
| 2010 | -0.51 |
| 2009 | -0.76 |
| 2008 | -0.77 |
Novacyt Revenue, EBIT, Net Income FR0010397232 · A12CFH
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Novacyt, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novacyt from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novacyt’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Novacyt. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Novacyt’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Novacyt’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novacyt’s growth potential.
Novacyt Revenue, EBIT and net profit per share
| Date | Novacyt Revenue | Novacyt EBIT | Novacyt Net Income |
|---|---|---|---|
| 2025e | 21.12 M undefined | 2.19 M undefined | 4.9 M undefined |
| 2024e | 72.92 M undefined | 19.81 M undefined | 15.89 M undefined |
| 2023 | 11.58 M undefined | -16.41 M undefined | -28.29 M undefined |
| 2022 | 21.04 M undefined | -15.73 M undefined | -25.73 M undefined |
| 2021 | 92.6 M undefined | 1.26 M undefined | -9.73 M undefined |
| 2020 | 277.2 M undefined | 174.69 M undefined | 132.42 M undefined |
| 2019 | 11.47 M undefined | -1.18 M undefined | -5.75 M undefined |
| 2018 | 12.2 M undefined | -848,827 undefined | -4.21 M undefined |
| 2017 | 11.33 M undefined | -1.66 M undefined | -4.84 M undefined |
| 2016 | 9.52 M undefined | -3.4 M undefined | -4.91 M undefined |
| 2015 | 8.89 M undefined | -3.31 M undefined | -13.91 M undefined |
| 2014 | 4.53 M undefined | -3.62 M undefined | -3.91 M undefined |
| 2013 | 1.15 M undefined | -1.06 M undefined | -1 M undefined |
| 2012 | 360,000 undefined | -570,000 undefined | -560,000 undefined |
| 2011 | 230,000 undefined | -690,000 undefined | -680,000 undefined |
| 2010 | 440,000 undefined | -510,000 undefined | -590,000 undefined |
| 2009 | 540,000 undefined | -760,000 undefined | -590,000 undefined |
| 2008 | 340,000 undefined | -770,000 undefined | -830,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2008 | 340,000 GBP | -770,000 GBP | -830,000 GBP |
| 2009 | 540,000 GBP | -760,000 GBP | -590,000 GBP |
| 2010 | 440,000 GBP | -510,000 GBP | -590,000 GBP |
| 2011 | 230,000 GBP | -690,000 GBP | -680,000 GBP |
| 2012 | 360,000 GBP | -570,000 GBP | -560,000 GBP |
| 2013 | 1.15 M GBP | -1.06 M GBP | -1 M GBP |
| 2014 | 4.53 M GBP | -3.62 M GBP | -3.91 M GBP |
| 2015 | 8.89 M GBP | -3.31 M GBP | -13.91 M GBP |
| 2016 | 9.52 M GBP | -3.4 M GBP | -4.91 M GBP |
| 2017 | 11.33 M GBP | -1.66 M GBP | -4.84 M GBP |
| 2018 | 12.2 M GBP | -848,827 GBP | -4.21 M GBP |
| 2019 | 11.47 M GBP | -1.18 M GBP | -5.75 M GBP |
| 2020 | 277.2 M GBP | 174.69 M GBP | 132.42 M GBP |
| 2021 | 92.6 M GBP | 1.26 M GBP | -9.73 M GBP |
| 2022 | 21.04 M GBP | -15.73 M GBP | -25.73 M GBP |
| 2023 | 11.58 M GBP | -16.41 M GBP | -28.29 M GBP |
| 2024e | 72.92 M GBP | 19.81 M GBP | 15.89 M GBP |
| 2025e | 21.12 M GBP | 2.19 M GBP | 4.9 M GBP |
Novacyt stock margins FR0010397232 · A12CFH
The Novacyt margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novacyt. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novacyt.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Novacyt's sales revenue. A higher gross margin percentage indicates that the Novacyt retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Novacyt's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Novacyt's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novacyt's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novacyt. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novacyt's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Novacyt Margin History
| Novacyt Gross margin | Novacyt Profit margin | Novacyt EBIT margin | Novacyt Profit margin |
|---|---|---|---|
| 2025e | 32.21 % | 10.38 % | 23.22 % |
| 2024e | 32.21 % | 27.16 % | 21.8 % |
| 2023 | 32.21 % | -141.72 % | -244.34 % |
| 2022 | 27.31 % | -74.76 % | -122.29 % |
| 2021 | 30.48 % | 1.36 % | -10.51 % |
| 2020 | 76.3 % | 63.02 % | 47.77 % |
| 2019 | 64 % | -10.25 % | -50.13 % |
| 2018 | 62.23 % | -6.96 % | -34.53 % |
| 2017 | 61.56 % | -14.67 % | -42.69 % |
| 2016 | 53.32 % | -35.71 % | -51.56 % |
| 2015 | 46.42 % | -37.24 % | -156.41 % |
| 2014 | 41.14 % | -79.89 % | -86.43 % |
| 2013 | 49.57 % | -92.17 % | -86.96 % |
| 2012 | -150 % | -158.33 % | -155.56 % |
| 2011 | -269.57 % | -300 % | -295.65 % |
| 2010 | -127.27 % | -115.91 % | -134.09 % |
| 2009 | -100 % | -140.74 % | -109.26 % |
| 2008 | -97.06 % | -226.47 % | -244.12 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2008 | -97.06 % | -226.47 % | -244.12 % |
| 2009 | -100 % | -140.74 % | -109.26 % |
| 2010 | -127.27 % | -115.91 % | -134.09 % |
| 2011 | -269.57 % | -300 % | -295.65 % |
| 2012 | -150 % | -158.33 % | -155.56 % |
| 2013 | 49.57 % | -92.17 % | -86.96 % |
| 2014 | 41.14 % | -79.89 % | -86.43 % |
| 2015 | 46.42 % | -37.24 % | -156.41 % |
| 2016 | 53.32 % | -35.71 % | -51.56 % |
| 2017 | 61.56 % | -14.67 % | -42.69 % |
| 2018 | 62.23 % | -6.96 % | -34.53 % |
| 2019 | 64 % | -10.25 % | -50.13 % |
| 2020 | 76.3 % | 63.02 % | 47.77 % |
| 2021 | 30.48 % | 1.36 % | -10.51 % |
| 2022 | 27.31 % | -74.76 % | -122.29 % |
| 2023 | 32.21 % | -141.72 % | -244.34 % |
| 2024e | 32.21 % | 27.16 % | 21.8 % |
| 2025e | 32.21 % | 10.38 % | 23.22 % |
Novacyt Aktienanalyse
What does Novacyt do?
Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics. Novacyt ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Novacyt's EBIT
Novacyt's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Novacyt's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Novacyt's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Novacyt’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Novacyt stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Novacyt.
How has the EBIT of Novacyt developed in recent years?
The EBIT of Novacyt has increased by -220.689% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Novacyt?
The EBIT of Novacyt is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Novacyt pay?
Over the past 12 months, Novacyt paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novacyt is expected to pay a dividend of 0 GBP.
What is the dividend yield of Novacyt?
The current dividend yield of Novacyt is .
When does Novacyt pay dividends?
Novacyt pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novacyt?
Novacyt paid dividends every year for the past 0 years.
What is the dividend of Novacyt?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novacyt located?
Novacyt is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novacyt kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novacyt from 9/10/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Novacyt pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Novacyt in the year 2023?
In the year 2023, Novacyt distributed 0 GBP as dividends.
In which currency does Novacyt pay out the dividend?
The dividends of Novacyt are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novacyt
Our stock analysis for Novacyt Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
